Feb 17, 2026 05:31PM
Feb 17, 2026 07:00AM
Feb 17, 2026 06:59AM
Dec 11, 2025 06:59AM
Dec 11, 2025 06:59AM
Oct 27, 2025 06:59AM
Oct 27, 2025 06:59AM Bristol Myers Squibb Presents Two Late-Breaking Presentations Demonstrating Sotyktu (deucravacitinib) Efficacy in Psoriatic Arthritis and Systemic Lupus Erythematosus
Oct 1, 2025 01:20PM
Aug 4, 2025 04:16PM
Aug 4, 2025 04:16PM
Jul 21, 2025 07:00AM
Jul 21, 2025 06:59AM
Apr 8, 2025 03:39PM
Apr 8, 2025 03:36PM U.S. Food and Drug Administration Approves Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a Treatment for Patients with Previously Untreated Microsatellite Instability-High or Mismatch Repair Defi
Mar 7, 2025 06:59AM
Mar 7, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 24, 2025 06:59AM
Feb 6, 2025 06:59AM
Jan 31, 2025 06:59AM
Jan 31, 2025 06:59AM Bristol Myers Squibb Receives Positive CHMP Opinion for Opdivo® (nivolumab) plus Yervoy® (ipilimumab) as a First-Line Treatment Option for Adult Patients with Unresectable or Advanced Hepatocellular
Dec 11, 2024 09:44AM
Oct 31, 2024 06:59AM
Sep 27, 2024 08:05AM
Sep 27, 2024 06:07AM
Sep 23, 2024 07:28AM
Aug 28, 2024 02:01AM
Aug 21, 2024 07:00AM Bristol-Myers Squibb (BMY) Announces FDA sBLA Acceptance for First-Line Treatment of Unresectable Hepatocellular Carcinoma
Aug 21, 2024 06:59AM
Jul 26, 2024 06:59AM
Jul 23, 2024 06:35AM
Jun 17, 2024 09:45AM
May 21, 2024 06:59AM
May 21, 2024 06:59AM
May 6, 2024 06:59AM Bristol-Myers Squibb (BMY) Announces FDA Acceptance of Application for Subcutaneous Nivolumab
May 6, 2024 06:59AM
Apr 25, 2024 06:59AM
Apr 25, 2024 05:22AM
Apr 8, 2024 11:31AM
Apr 8, 2024 11:30AM
Apr 1, 2024 07:31AM
Apr 1, 2024 07:30AM Zai Lab Partner Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRA
Mar 28, 2024 04:07PM
Mar 28, 2024 04:05PM
Mar 18, 2024 09:52AM
Mar 18, 2024 08:45AM
Mar 18, 2024 08:44AM
Feb 20, 2024 06:59AM
Feb 20, 2024 06:59AM U.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Tr
Feb 14, 2024 08:30AM

14,982 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All